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Abstract
Background: Human dermal mesenchymal stromal cells (MSCs) expressing the ATP-binding cassette (ABC) efflux
transporter ABCB5 represent an easily accessible MSC population that, based on preclinical and first-in-human data,
holds significant promise to treat a broad spectrum of conditions associated not only with skin-related but also
systemic inflammatory and/or degenerative processes.
Methods: We have developed a validated Good Manufacturing Practice-compliant expansion and manufacturing
process by which ABCB5+ MSCs derived from surgical discard skin tissues are processed to an advanced-therapy
medicinal product (ATMP) for clinical use. Enrichment for ABCB5+ MSCs is achieved in a three-step process
involving plastic adherence selection, expansion in a highly efficient MSC-selecting medium, and immunomagnetic
isolation of the ABCB5+ cells from the mixed culture.
Results: Product Quality Review data covering 324 cell expansions, 728 ABCB5+ MSC isolations, 66 ABCB5+ MSC
batches, and 85 final drug products reveal high process robustness and reproducible, reliable quality of the
manufactured cell therapy product.
Conclusion: We have successfully established an expansion and manufacturing process that enables the
generation of homogenous ABCB5+ MSC populations of proven biological activity manufactured as a standardized,
donor-independent, highly pure, and highly functional off-the-shelf available ATMP, which is currently tested in
multiple clinical trials.
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Background
While mesenchymal stromal cells (MSCs) for thera-
peutic use are most frequently obtained from bone mar-
row, followed by adipose tissue and puerperal tissues
such as umbilical cord and placenta, MSCs can be iso-
lated from a far greater variety of human tissues [1–3].
Human skin, representing a particularly easily accessible
tissue that offers the use of surgical discard tissue, har-
bors a highly potent immunomodulatory cell population
marked by the plasma membrane-spanning ATP-
Binding Cassette Transporter, Subfamily B, Member 5
(ABCB5) [4]. Human skin-derived ABCB5+ cells display
typical MSC characteristics as defined by the Inter-
national Society for Cellular Therapy [5], including ad-
herence to plastic surfaces; clonogenicity; expression of
CD90, CD73, and CD105; lack of hematopoietic lineage
markers CD45, CD34, and CD14; increased osteogenic,
adipogenic, and chondrogenic differentiation potential as
compared with donor-matched ABCB5− fibroblasts [6];
and trans-differentiation into CD31+ endothelial cells
[7]. In addition to their (trans-) differentiation potential,
ABCB5+ MSCs have shown marked immunomodulatory
effects through interaction with macrophages [6], neu-
trophils [8], and regulatory T cells [9], as well as a strong
paracrine capacity including adaptive release of vascular
endothelial growth factor (VEGF) and interleukin 1 re-
ceptor antagonist (IL-1RA) [6, 7].
Covering all three principal mechanisms (i.e., immu-
nomodulation, adaptive secretion of anti-inflammatory
and pro-angiogenic biomolecules, and multilineage
differentiation) by which MSCs can contribute to in-
flammation control and tissue repair, skin-derived
ABCB5+ MSCs offer a broad spectrum of potential
therapeutic indications associated not only with skin-
related but also systemic inflammatory and/or degen-
erative processes. In preclinical studies, ABCB5+
MSCs delivered significant benefit in mouse models
of chronic skin wounds [6], epidermolysis bullosa
[10], and liver disease [11]. In a first in-human clin-
ical trial, topically applied ex vivo-expanded ABCB5+
MSCs facilitated wound closure of standard therapy-
resistant chronic venous ulcers [7].
Aiming at developing human skin-derived ABCB5+
MSCs for clinical use as an advanced-therapy medicinal
product (ATMP), we have developed and validated a
Good Manufacturing Practice (GMP)-compliant ex vivo
expansion and manufacturing process to reliably, repro-
ducibly, and efficiently generate highly pure ABCB5+
MSCs of proven biological potency that can be instantly
manufactured as an off-the-shelf product at a clinical
scale. Enrichment for ABCB5+ MSCs, which account for
roughly 2–3% of the total dermal cell population [6, 12],
is achieved in a three-step process involving selection
upon plastic adherence, ex vivo cell expansion in a
highly efficient MSC-selecting medium, and immuno-
magnetic isolation of the ABCB5+ cells from the mixed
culture, making use of an antibody specifically directed
against an extracellular loop of the ABCB5 molecule [4].
This product has been tested in a thorough preclinical
biodistribution, toxicity, and tumorigenicity study pro-
gram, which has revealed a favorable safety profile after
subcutaneous, intramuscular, and intravenous single-
and repeated-dose application [13]. Currently, our prod-
uct is being assessed in several multicentric national and
international clinical trials evaluating its safety and effi-
cacy in various chronic inflammatory and degenerative
conditions (Table 1).
Here we present our expansion and manufacturing
process and report on GMP Product Quality Review data
for 66 ABCB5+ MSC (“drug substance”) batches and 85
final drug products manufactured between January 2018
and September 2019. While process validation data have
been recently published [7], we focus here on the routine
GMP manufacturing process of the medicinal product,
particularly on process homogeneity, comparability be-
tween batches derived from different passages and donors,
and potency testing.
Methods
Tissue procurement and processing
Skin samples (≥ 10 cm2) were obtained in accordance
with the German Medicines Act (“Arzneimittelgesetz”)
and the German Act on Organ and Tissue Donation, Re-
moval and Transplantation (“Transplantationsgesetz”) as
discard tissues from plastic surgeries (abdominoplasties
and mastopexies) from donors aged ≤ 50 years who had
given written informed donor consent. Tissues from do-
nors who tested serologically positive for HIV1/2, HBV,
HCV, HTLV1/2, or syphilis were discarded.
Skin processing and stem cell production took place in
an EU-GMP grade A cabinet in a grade B clean room
under laminar air flow (“A in B”). Skin tissue was freed
from excess subcutaneous tissue, disinfected, washed,
dissected into equal pieces (about 2.5 cm2), and sub-
jected to two-step enzymatic digestion using collagenase
(Collagenase NB 6 GMP Grade, Nordmark, Uetersen,
Germany) followed by animal component-free trypsin
(Recombinant Trypsin Solution, Biological Industries,
Beit Haemek, Israel). After filtration and washing/centri-
fugation of the filtrates, pellets were resuspended in an
in-house MSC-favoring growth medium (Ham’s F-10
supplemented with fetal calf serum, L-glutamine,
fibroblast growth factor-2, HEPES, hydrocortisone, insu-
lin, glucose, and phorbol myristate acetate), pooled, and
incubated in C6 cell culture plates in a cell culture
incubator at 3.1% CO2 (as instructed by the Ham’s F-
10 manufacturer, Biochrom, Berlin, Germany), 90%
humidity, 37 °C.
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Assessment of cell confluency and morphology
During the whole cell expansion and subcultivation
process, cell confluency and morphology were assessed
visually under a phase-contrast microscope by compre-
hensively trained lab assistants strictly applying the four
eyes principle (i.e., cross-checked by the Head of Pro-
duction). Sets of standardized photographs of cultures at
different stages of confluency as well as typical and un-
typical or artificial cell morphology are used as reference
for comparison. A photograph displaying a cell mono-
layer at 70% confluency is shown in (Fig. S1 (see
Additional file 2)).
Cell expansion
Cells were expanded as unsegregated (“mixed”) cell cul-
tures in up to 30 parallel batches from C6 well via T25
and T75 to 8 × T175 culture flasks by serial passaging
(six passages). During cultivation, regular, protocol-
defined medium changes facilitated depletion of non-
adherent cells from the culture. Having grown to 70%
confluency, cells were harvested using recombinant tryp-
sin and transferred to the next larger culture vessel at a
seeding density of 3 × 104 cells/cm2. When 8 × T175
flasks had been reached, four flasks were harvested to be
cryopreserved as primary mixed culture for internal
back-up purposes. The remaining four flasks were fur-
ther subcultivated to 16 × T175 flasks for magnetic sep-
aration of the ABCB5+ cells, respectively (Fig. 1).
Isolation of ABCB5+ cells and batch pooling
After reaching 75% confluency, ABCB5+ MSCs were iso-
lated using magnetic beads (micromer® TC1 Epoxy,
Micromod, Rostock, Germany) coated with a mouse
anti-human monoclonal antibody directed against the
sequence 493–508 (RFGAYLIQAGRMTPEG) of the
ABCB5 extracellular loop 3 [4] (Maine Biotechnology
Services, Portland, Maine; GMP purification: Bibitec,
Bielefeld, Germany; ICH Q5 [14] virus depletion and
safety study: Charles River, Erkrath, Germany). The
manufacturing protocol allows for multiple successive
isolation cycles, by using only 12 of 16 × T175 flasks for
ABCB5+ cell isolation, while the remaining four flasks
are further subcultivated to generate 16 × T175 flasks
(see Fig. 1). This cycle may be repeated until passage
number 16 [7], provided that no changes in cell morph-
ology or growth behavior occur. If required, the cryopre-
served back-up mixed culture can be thawed and
subcultivated for further cell production and isolation.
All ABCB5+ cell isolates from one and the same donor
tissue that had been isolated in parallel (i.e., on the same
day at the same passage number) were pooled to gain
one drug substance batch. Each batch was then divided
into multiple aliquots of 2 × 106–18 × 106 cells, which
were cryopreserved (CryoStor® CS10 freeze medium,
BioLife Solutions, Bothell, Washington) and stored in
the vapor phase of liquid nitrogen.
Drug product formulation
The final drug product was manufactured as an investi-
gational medicinal product to be tested in various clin-
ical trials (Table 1). It was formulated as a ready-to-use
suspension, with total cell count and packaging size de-
pending on the intended application. The required quan-
tity of cryopreserved drug substance aliquots, originating
from one and the donor skin tissue, were thawed,
pooled, washed, and suspended in HRG solution
(Ringer’s lactate solution containing 2.5% human serum
albumin and 0.4% glucose) at a target concentration of
1 × 107 cells/ml. The cell suspension was filled in one or
multiple 1-ml polycarbonate or 10-ml polypropylene sy-
ringes (BD Plastipak™, Becton Dickinson, Heidelberg,
Germany), as required, which were sealed with poly-
ethylene closing cones (Combi-Stopper, B. Braun, Mel-
sungen, Germany).
In-process controls and release tests
In-process and release tests followed validated GMP-
compliant procedures according to the requirements of
the European Pharmacopoeia, if applicable. A schematic
overview is given in Fig. 1, and the specifications are
given in Table S1 (see Additional file 1).
Cell cycle analysis
Immediately before the magnetic separation of ABCB5+
cells, a sample containing about 2 × 106 cells of the
mixed culture were fixed with ice-cold 70% ethanol
(added dropwise while vortexing) for at least 30 min at
4 °C. After washing in 0.02% EDTA, cells were resus-
pended in RNase A (Thermo Fisher)/propidium iodide
solution and analyzed by flow cytometry (BD Accuri™
C6; Becton Dickinson, Heidelberg, Germany) using
standard gating strategies.
Determination of ABCB5+ cell content
Following the ABCB5+ cell isolation, but before the en-
zymatic detachment of the microbeads (which leads to a
transient loss of ABCB5 from the cell surface), ABCB5+
cell content was determined after incubation with an
Alexa Fluor® 647-coupled donkey anti-mouse secondary
antibody (Thermo Fisher, Langenselbold, Germany) tar-
geting the anti-ABCB5 antibody used for the cell isola-
tion. To discriminate between ABCB5+ cells and free
bead-antibody complexes, calcein acetoxymethylester
(staining metabolically active cells) was added to the
cell-secondary antibody suspension before incubation.
Fluorescence was measured by flow cytometry (BD
Accuri™ C6, Becton Dickinson). Free, unbound bead-
antibody complexes were excluded from the ABCB5+
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cell content calculation by gating only events with high
calcein fluorescence.
Mycoplasma testing
Supernatant and cell suspension samples were spiked
with internal control DNA, and genomic DNA was iso-
lated using the Microsart AMP Extraction Kit (Minerva
Biolabs, Berlin, Germany). Isolated DNA was subjected
to qPCR including positive and negative controls and
10CFU™ Sensitivity Standards for Mycoplasma (M.)
orale, M. fermentans, and M. pneumoniae (Microsart
ATMP Mycoplasma Kit; Minerva Biolabs).
Endotoxin testing
After the ABCB5+ cell isolation, microbead detachment,
and washing/centrifugation of the cell suspension, a
Fig. 1 Flow chart summarizing the manufacturing process of human skin-derived ABCB5+ mesenchymal stem cells. IPC in-process control, mCcP
microbiological control of cellular product, MK mixed (unsegregated) culture
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supernatant sample was diluted 1:10 with Endosafe®
Limulus Amebocyte Lysate Reagent Water and trans-
ferred into an Endosafe® PTS™ cartridge (limit of detec-
tion 0.05 EU/ml), which was loaded into an Endosafe®
PTS™ reader (all from Charles River, Charleston, South
Carolina). The endotoxin level of the sample was calcu-
lated based on the change in optical density analyzed
against an internal standard curve.
Determination of live cell count and vitality
Propidium iodide solution (1 mg/ml) was added to a cell
suspension sample from each drug substance batch and
from each produced drug product to stain dead cells.
Fluorescence was measured using flow cytometry (BD
Accuri™ C6) and cell count and vitality, defined as per-
centage of propidium iodide-excluding cells, calculated.
Determination of viability, CD90 expression, and bead
residues
Viability, CD90 expression, and microbead residues,
which might result from insufficient bead detachment or
cell washing, were analyzed in parallel. From each drug
substance batch, a sample was incubated with calcein
acetoxymethylester and an Alexa Fluor® 647-conjugated
anti-human CD90 antibody (BioLegend, London, UK).
Fluorescence was analyzed by flow cytometry (BD
Accuri™ C6), and the viability of the cell population (de-
fined as percentage of metabolically active cells, i.e., cells
converting calcein acetoxymethylester to calcein) and
the content of CD90+ cells were calculated. To detect re-
sidual beads, a sample of ABCB5 antibody-conjugated
beads was used to define a gate in the FSC/SSC dot plot.
To exclude (false-positive) signals, only calcein-negative
events in that gate were used to calculate bead residues.
Microbiological examination
Microbiological examination was carried out by a certi-
fied academic contract laboratory. Samples from every
single cryovial of each drug substance batch and from
each produced drug product were diluted in NaCl-
peptone buffer, inoculated in BACT/ALERT® BPN (an-
aerobic) and BACT/ALERT® BPA (aerobic) culture bot-
tles (bioMérieux, Nürtingen, Germany), and incubated
in the BACT/ALERT® 3D60 (bioMérieux) microbial de-
tection system. Positive samples were seeded onto solid
culture medium immediately after detection. After 7
days of incubation, all negative samples were seeded
onto solid culture medium.
IL-1RA secretion assay
Human monocytic cells (THP-1; LGC Standards, Wesel,
Germany) were differentiated into macrophages by incu-
bation in differentiation medium containing 150 nmol/
ml phorbol 12-myristate 13-acetate for 48 h at 37 °C, 5%
CO2. In two wells of a 24-well plate, 1 × 10
5 macro-
phages were co-cultivated with 2 × 104 ABCB5+ MSCs.
In one of the two wells, M1 polarization was stimulated
by adding 50 IU/ml interferon-γ (Imukin®, Clinigen
Healthcare, Burton-upon-Trent, UK) at the start of
cocultivation, and 50 IU/ml interferon-γ and 20 ng/ml li-
popolysaccharides from Escherichia coli O111:B4
(Sigma-Aldrich) after 24 h. After 48 h, supernatants were
collected and analyzed for IL-1RA using a colorimetric
sandwich ELISA kit (Quantikine®, R&D Systems, Abing-
don, UK) according to the manufacturer’s instructions.
VEGF secretion assay
ABCB5+ MSCs (3 × 105) were seeded into a culture dish
in stem cell medium and incubated under hypoxic con-
ditions (1% O2) at 37 °C. After 48 h, supernatants were
collected and analyzed using the Invitrogen VEGF Hu-
man ELISA Kit (Thermo Fisher) according to the manu-
facturer’s instructions.
Tube formation assay
ABCB5+ MSCs (1 × 105 and 1.5 × 105) were seeded in
two wells of a 24-well plate coated with Geltrex® base-
ment membrane matrix (Thermo Fisher) and incubated
in stem cell medium for 19–22 h at 37 °C, 3.1% CO2.
Tube structures were photographed using an inverted
microscope (40× final magnification; DM IL LED, Leica,
Wetzlar, Germany) equipped with a digital camera
(DFC320, Leica) and semi-quantitatively classified into
six (A–F) categories, ranging from A = tubular branches
of several cells forming a defined network-like structure
to F = no tubular branches visible (Fig. S2 (see Add-
itional file 2)), with A–C being considered as successful
angiogenic differentiation. For assay validation, human
umbilical vein endothelial cells (Thermo Fisher) and hu-
man skin melanoma cells (SK-MEL-28, ATCC® HTB-
72™, LGC Standards, Wesel, Germany) were used as
positive and negative controls, respectively.
Determination of MSC markers
In addition to routine determination of CD90+ cell con-
tent (see the “In-process controls and release tests” sec-
tion), the batches intended for use at study sites in the
Czech Republic in the multinational clinical trial on per-
ipheral artery disease (NCT03339973, Table 1) were
additionally tested for expression of CD73, CD105, und
CD44 [5, 15], as required by the Czech national drug au-
thority (State Institute for Drug Control, SÚKL). To this
end, cell suspension samples were incubated with a
fluorescein isothiocyanate (FITC)-conjugated anti-
human CD73 antibody, an Alexa Fluor® 647-conjugated
anti-human CD105 antibody, and a FITC-conjugated
anti-human CD44 antibody (all from BioLegend), re-
spectively. Fluorescence was measured by flow cytometry
Ballikaya et al. Stem Cell Research & Therapy          (2020) 11:482 Page 6 of 15
(BD Accuri™ C6) and percentages of CD73+ CD105+ and
CD44+ cells were calculated. Pre-specified acceptance
criteria were CD73, ≥ 95% [5]; CD105, determined and
declared; and CD44, determined and declared.
Results
Starting material
Between July 2017 and September 2019, we received
skin donations from twelve donors obtained in two der-
matological clinics approved as tissue retrieval facilities
according to §20b German Medicines Act (“Arzneimit-
telgesetz”). Ten of these skin donations were left-over
tissues from abdominoplasties, the remaining two from
plastic breast surgeries. All donors were female and be-
tween 28 and 49 years of age.
Five of the twelve skin specimens were rejected and
discarded before or retroactively during processing for
various reasons including fungal contamination of the
transport medium (n = 2), bacterial contamination of the
cleanroom (n = 1), and cell morphology changes during
culture (n = 2). All data in this report relate to the
remaining seven skin donations that fulfilled the specifi-
cations for tissue release.
Cultivation time
Homogeneity of the expansion process was evaluated by
analysis of the cultivation time, i.e., the time periods be-
tween passaging and reaching ≥ 70% confluency (as the
threshold for the next split/passaging of the culture) in
the culture vessel. Figure 2a summarizes the cultivation
times until passage 6 for 324 expansions carried out be-
tween January 2018 and September 2019. All cultures
met the specified upper time limit (16 days for cultiva-
tion until the first passage and 7 days for the subsequent
Fig. 2 Intra-donor mean (+ SD) cultivation times of mixed (unsegregated) cell cultures. a Mean cultivation times during cell expansion from
culture initiation until passage 6 shown by passage (left panel) and in total (right panel). Black dotted lines indicate passage means. b Mean
duration of subcultivation (from 4 to 16 × T175 culture flasks) before isolation of the ABCB5+ cells from fresh (left panel) and from previously
cryopreserved/thawed cultures (right panel) for up to four isolation cycles. Fresh cultures: isolation cycles 1–4 correspond to passages 7–10;
thawed cultures: isolations cycles 1–3 correspond to passages 9–11. Data represent all expansions and isolation cycles performed between
January 2018 and September 2019; therefore, for donors 1 and 2, only thawed cultures are shown (because expansion and isolation from fresh
cultures had been performed before January 2018). Red dashed lines indicate the upper time limit; if a culture had not reached target confluency
within this prespecified period, it would have been discarded
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passages; based on validation data showing that cultures
that require longer time periods to reach the target con-
fluency will nearly totally stop growth at later stages of
the expansion process due to senescence, differentiation
and morphology changes). The mean cultivation time
from initiation of culture until generation of eight con-
fluent T175 flasks was 30.5 days, with the inter-donor
range of 29.0 to 32.4, corresponding to a maximal differ-
ence of means between donors of 10.2% (right panel).
Next, the time intervals needed for subcultivation of
4 × T175 flasks to 16 × T175 flasks at ≥ 75% confluency
(as the threshold for isolation of the ABCB5+ cells from
the unsegregated subcultures) were evaluated. Figure 2b
summarizes the results for immediately subcultivated
(“fresh”) cultures (left panel) and for primary cultures
that had been cryopreserved (“thawed”) (right panel).
Similar to what was seen during the expansion process,
the specified upper limit (10 days) for subcultivation was
met in all cases. Also, consistently low intra-donor
standard deviations and narrow inter-donor ranges
(fresh cultures, 5.7–7.4 days; thawed cultures, 6.4–7.5
days) indicate a high level of homogeneity of the subcul-
tivation process within as well as between the different
donors, irrespective of whether fresh cultures or cultures
that had been cryopreserved and thawed prior to subcul-
tivation were used.
Cell cycle phase distribution
Cell cycle analysis, which is performed as an in-process
control before isolation of the ABCB5+ cells from the
mixed culture, revealed a phase distribution of 82% (±
6%) of cells in G1, 3% (± 2%) in S, and 10% (± 4%) in
G2/M phase (Fig. 3a). The distribution pattern did not
differ between donors (Fig. 3b) nor change during passa-
ging (Fig. 3c).
Drug substance analyses
Between January 2018 and September 2019, 728
ABCB5+ cell isolates were obtained, which were pooled
to 66 “drug substance” batches. Of these, 47 batches,
made up of 548 single cell isolates in total, were released
for final drug production.
ABCB5+ cell isolate evaluation
The mean live cell count of the ABCB5+ cell isolates var-
ied between donors, ranging from 19.0 × 106 ± 5.5 × 106
(donor 2) to 48.6 × 106 ± 16.9 × 106 (donor 7). These inter-
donor variations in ABCB5+ MSC yield did not correlate
with donor age (Table S2 (see Additional file 1)).
In order to identify potential lab assistant-related influ-
ences on the ABCB5+ cell isolation performance, we
aimed to assess to what extent the cell count isolated by
the assistant differs from the mean cell count of all
batches that were isolated in parallel (i.e., on the same
day from the same donor and same passage) for each lab
assistant. As shown in Fig. 4, the amount of isolated
ABCB5+ cells by each lab assistant expressed as the
mean percentage from the mean live cell count of all
isolates that were afterwards pooled to the same drug
substance batch varied between the lab assistants from
about 40 to 140% (for all assistants who had carried out
Fig. 3 Cell cycle analysis of the primary cultures used for production
of 66 drug substance batches. a Percentages of cells in G1, S, and
G2/M phases shown for each culture. b Data from (a) grouped by
donors. c Data from (a) grouped by passage number. Error bars
indicate means ± SD
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at least 10 isolations). When only the more experienced
lab assistants (i.e., who had carried out at least 20 isola-
tions) were considered, the range was 75–125%.
To limit a potential impact of variability between the
ABCB5+ cell isolates on drug substance batch homogen-
eity and quality, each set of parallelly obtained isolates is
only released as a whole for drug substance batch pool-
ing, if the coefficient of variation of the cell count does
not exceed 50%; otherwise, only those isolates of the set
are released, whose cell counts do not differ by more
than 50% from the mean cell count. Of 66 cell isolate
sets that were pooled to 66 drug substance batches, 64
sets proved entirely “poolable” and were released as a
whole. From the remaining 2/66 cell isolate sets, 2/10
and 3/6 isolates, respectively, had to be rejected due to
> 50% deviation from the mean cell count of the set, so
that 8/10 and 3/6 isolates, respectively, could be released
for drugs substance batch pooling.
Drug substance batch evaluation
Of the 66 drug substance batches that were produced
between January 2018 and September 2019 (Table S3
(see Additional file 1)), 9 batches were rejected by the
quality control unit due to out-of-specification results
[limit value (< 1 CFU) exceedance for environmental
microbiological monitoring (n = 1), release parameter de-
viation from the specified acceptance criterion (n = 8;
Table 2)], 10 batches were used for research and devel-
opment purposes, and 47 batches were released for final
drug product manufacturing.
To detect a potential impact of the level of cell passa-
ging on drug substance batch homogeneity and quality,
the release parameters live cell count, vitality, viability,
and ABCB5+ cell content were also evaluated in relation
to the passage number at which the ABCB5+ cells were
isolated from the mixed culture. Neither of these param-
eters showed any passage number-dependent variation
(Fig. 5a).
Potency testing
All 66 drug substance batches fulfilled the specification
for anti-inflammatory (IL-1RA secretion in response to
stimulation by M1-polarized macrophages) and pro-
angiogenic [VEGF secretion after 48 h hypoxia potency
(Table 2)], with donor means ranging from 2.6 ± 2.0
(donor 7) to 4.6 (n = 1) (donor 1) for IL-1RA ratiostim/un-
stim and from 396 ± 85 pg/ml (donor 2) to 1183 ± 278 pg/
ml (donor 4) for VEGF supernatant concentration
Fig. 4 Lab-assistant-specific performance of ABCB5+ cell isolation. Performance is expressed as the mean percentage (± SD) from the mean live
cell count of all ABCB5+ cell isolates that were afterwards pooled to the same drug substance batch. Cell counting was performed strictly
independently from the lab assistant by the quality control department using a standardized automated method (flow cytometry). Included in
this analysis are all lab assistants who had carried out at least 10 isolations (n = 721 isolations in total), with the less experienced lab assistants
(10–19 isolations) colored in light blue and the more experienced (≥ 20 isolations) in median blue. *p < 0.05 (one-way ANOVA with Bonferroni’s
post hoc test) vs. the most experienced assistant (G, dark blue). Note that the letters A–N identifying the lab assistants are arbitrarily assigned
based on the order of data arrangement and do not match with those used in Fig. 6
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(Fig. 5b). All but 3 (4.5%) of the 66 drug substance
batches tested positive in the endothelial trans-
differentiation assay as shown by capillary structure for-
mation by at least one of two cell concentrations seeded
in extracellular matrix (Fig. 5b, Table 2).
MSC marker expression
Determination of MSC marker expression in 17 drug
substance batches derived from 3 donors (i.e., the
batches intended for use at study sites in the Czech Re-
public, as required by the Czech national drug authority)
revealed that the markers CD90, CD73, CD105, and
CD44 were expressed by 99.6 ± 0.9%, 99.8 ± 0.2%, 99.5 ±
0.8%, and 99.5 ± 0.9% of cells, respectively. All batches
met the pre-specified criteria for batch release.
Final drug product
Between January 2018 and September 2019, 85 drug
products used as investigational medicinal products in
clinical trials were manufactured (for overview see
Table 1). All products met the pre-specified criteria
(Table S1) for batch release.
Final product manufacturing process was associated
with a mean cell count loss (most likely related to
freeze/thaw losses and process steps such as transfer,
washing, and centrifugation) of 24.9 ± 14.5%, which was
comparable between the different skin donors, with
donor means ranging from 19.3 ± 12.6% (n = 12, donor
4) to 27.3 ± 15.4% (n = 5, donor 7) (Fig. 6a). Cell count
loss was also comparable between 10 out of the 11 lab
assistants who carried out the formulation processes in-
cluding all the critical process steps at which process-
related cell loss might occur, with assistant-related mean
cell count loss ranging from 18.0 ± 17.3% (n = 8) to
29.8 ± 8.5% (n = 10). Only for one lab assistant, a greater
mean cell loss (37.4 ± 14.6%, n = 4) as compared to the
other assistants was observed (Fig. 6b).
Determination of MSC marker expression in 5 drug
products derived from 3 donors (i.e., the drug products
intended for use at study sites in the Czech Republic, as
required by the Czech national drug authority) revealed
CD90, CD73, CD105, and CD44 expression by 99.9 ±
0.1%, 100 ± 0.1%, 99.5 ± 0.5%, and 100 ± 0.0% of cells,
respectively.
Discussion
Aiming at enabling safe, effective, and reproducible
therapeutic use of donor-derived dermal ABCB5+ MSCs,
we developed and validated a GMP-compliant ex vivo
expansion and manufacturing process to generate an
Table 2 Results from drug substance release testing (n = 66 batches derived from 7 donors)
Parameter Specification Result Deviations
absolute %
ABCB5+ cell content ≥ 90% 97.72 ± 1.88% 1a 1.5a
Mycoplasma Not detectable (< 10 CFU/ml) Not detectable in 65/66 batches 1 1.5
Endotoxin level ≤ 2 EU/ml ≤ 2 EU/ml in 66/66 batches 0 0
Live cell count n.a.b 275.33 × 106 n.a.b n.a.b
Deviation of live cell count from
expected valuec
≤ 30% ≤ 30% in 46/49 batchesd 3 6%d
Cell vitalitye ≥ 90% 98.60 ± 0.62% 0 0
Cell viabilityf ≥ 90% 99.45 ± 0.64% 0 0
CD90+ cell content ≥ 90% 99.45 ± 0.50% 0 0
Bead residues ≤ 0.5% 0.04 ± 0.05% 0 0
Microbiological control No growth No growth in 66/66 batches 0 0
IL-1RA secretion > 125 pg/ml and ratiostim/unstim > 1 > 125 pg/ml and ratiostim/unstim > 1 in 66/
66 batches
0 0
VEGF secretion > 46.9 pg/ml > 46.9 pg/ml in 66/66 batches 0 0
Angiogenic differentiation Capillary structures in one or both seeded cell
concentrations
positive in 63/66 batches 3 4.5%
Numeric results are given as mean ± SD
n.a. not applicable
aFor one batch, measurement procedure was not fully GMP-conform. Although this did not affect the result, the batch was not released for drug production
bAcceptance criteria for cell count are only defined for the aliquots into which the drug substance batches are divided for cryostorage, not for the batch as
a whole
cExpected value = sum of the live cell counts of all ABCB5+ cell isolates that were pooled to produce the drug substance batch
dThe criterion “Deviation of live cell count from expected value” was implemented only from donor 4 on, which is the reason for the lower sample
number (n = 49)
eVitality was defined as percentage of live cells, defined as propidium iodide-excluding cells
fViability was defined as percentage of metabolically active cells, defined as cells converting calcein acetoxymethylester to calcein
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Fig. 5 Results from drug substance batch quality control analyses. a Live cell count, vitality, viability and ABCB5+ cell content of the 66 produced
drug substance batches as determined before cryopreservation, shown by the number of the passage at which the ABCB5+ cells were isolated
from the mixed culture. b Anti-inflammatory and proangiogenic potency of ABCB5+ mesenchymal stromal cells (MSCs) as measured by secretion
of interleukin-1 receptor antagonist (IL-1RA) after stimulation by M1-polarized macrophages (IL-1RA secretion assay; given as ratio to IL-1RA
secretion observed with unstimulated ABCB5+ MSCs), secretion of vascular endothelial growth factor (VEGF) after 48-h culture under hypoxic
conditions (VEGF secretion assay; *value above upper limit of assay range, i.e., > 1500 pg/ml), and capillary structure formation in extracellular
matrix (tube formation assay; red bar segments indicate the batches that failed to clearly form capillary structures). Error bars indicate means ± SD
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ATMP derived from skin tissue donations that guarantees
reliable and reproducible cell quality and functionality
while being deliverable as an instantly available off-the-
shelf product.
From experience with MSCs derived from bone mar-
row or adipose tissue, it is known that age and morbid-
ities of the donor can impair the number, viability,
proliferation capacity, maximum life span, and func-
tional properties such as differentiation potential and
proangiogenic factor secretion [16–24]. For dermal
ABCB5+ MSCs, an age-dependent decrease in their
number in situ from 3.2% of total dermal cells in the
skin of young individuals to 1.6% of total dermal cells in
the skin of individuals > 70 years has been observed [12].
Together, these observations prompted us to limit donor
age to ≤ 50 years and to define strict donor health re-
quirements. Nevertheless, even MSCs derived exclusively
from young and healthy donors have been described to
exhibit donor-dependent variations in molecular status,
growth behavior, and functional characteristics [25, 26],
which, ultimately, could result in donor-related batch-
to-batch variability. Other factors that could potentially
contribute to unwanted product inhomogeneity may be
related to variations in the expansion and manufacturing
process such as passage number or lab assistant experi-
ence. In this context of a situation where the “process is
the product” [1, 27], it is crucial to closely monitor the
entire process at each step from the starting material
until the final drug product to detect and eliminate any
factors that would impair the homogeneity of the cell
therapy product.
During cultivation, potential donor and/or passage
number-related variations in the proliferative capacity of
the cultured cells were monitored by assessing the time
needed from passaging to reach the target confluency
for each passage. In all cases, the specified upper time
limits during both expansion (passages 1–6) and subcul-
tivation (up to passage 11, depending on the number of
isolation cycles performed) were met (Fig. 2). Low intra-
donor standard deviations and generally narrow inter-
donor ranges indicate high homogeneity of the prolifera-
tive behavior of the cells within and between the differ-
ent donors, respectively. This is supported by previous
cell division data collected during the process validation
phase, which revealed a constant mean division rate of
0.35 divisions per day across 15 donors and even up to
16 passages [7]. It should be noted that the number of
isolation cycles (which accounted for up to 11 passages
at maximum) for each donor depended on the com-
pany’s production plan and were, in most cases, not re-
strained by cell culture-related phenomena such as
changes in cell morphology or growing behavior.
Low variation within donors and a high degree of
comparability between donors was also seen for the cell
cycle distribution of ABCB5+ MSCs (Fig. 3). The phase
distribution pattern (82 ± 6%, 3 ± 2%, and 10 ± 4% for
G1, S, and G2/M phase, respectively) resembled exten-
sive data collected during process validation (503 ana-
lyses from 260 donors: 72.4 ± 8.5%, 4 ± 2.9%, and 15 ±
8.5% for G1, S, and G2/M phase, respectively) [7] and
did not change during passaging until passage 11
Fig. 6 Cell count loss during final drug product manufacturing from
cryopreserved drug substance aliquots. a Cell count loss shown by
tissue donor. b Cell count loss shown by lab assistant. Cell count
loss is expressed as percentage difference between the expected (as
calculated from the number and the cell content of the aliquots)
and the actual final cell count. Shown are means ± SD of n
manufactured products; blue dotted lines indicate mean cell count
loss of all 85 produced drug products. Note that the letters A–K
identifying the lab assistants are arbitrarily assigned based on the
order of data arrangement and do not match with those used
in Fig. 3
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(Fig. 3c). Taken together with previous RNA sequence
analysis data revealing that the expression of various
stemness and mesenchymal marker genes was not al-
tered in ABCB5+ MSCs expanded to high passage num-
bers (> 10) as compared to low passage numbers (2–3)
[6] and microarray data (GEO accession No.
GSE145589) showing that the gene expression profile of
ABCB5+ MSCs did not significantly change over five
delta passages up to passage 16 [7], these results support
that proliferation capacity and MSC properties of
ABCB5+ MSCs are maintained during ex vivo expansion
up to comparatively late passages.
The isolation process of ABCB5+ MSCs from the ex-
panded mixed cell culture was evaluated by assessing the
homogeneity of the ABCB5+ cell isolates and the quality
of the drug substance batches produced thereof. Obvi-
ously, the cell isolates varied considerably in their mean
live cell count between the different donors, with the
highest donor mean (48.6 × 106 ± 16.9 × 106 cells per iso-
late) amounting to more than twofold of the lowest
donor mean (19.0 × 106 ± 5.5 × 106 cells per isolate)
(Table S2). This donor-related variation was neither
dependent on donor age, sex (all donors were female)
nor skin tissue localization (abdomen vs. mamma)
(Table S2) and may therefore reflect other, likely individ-
ual, differences between donors. In this regard, please
note that the use of female donors in this study occurred
by chance (the plastic surgeries in our collaborating tis-
sue retrieval facilities from which we obtained our start-
ing materials were coincidentally underwent by female
subjects) and does not reflect a preference of female to
male donors. Variations in the mean live cell count of
the cell isolates were also observed between the different
lab assistants who performed the ABCB5+ cell isolation.
From our experience, a certain degree of variation can
be expected based on the various processing steps such
as harvest, isolation, washing, resuspension, and sam-
pling. As it turned out, the degree of variation declined
with increasing experience of the lab assistant. In con-
trast to lab assistant-related variability, the number of
passages that a culture had undergone until ABCB5+ cell
isolation did not appear to have impact on the live cell
count of the isolate, since vitality and viability of the iso-
lated cells did not change with increasing passage num-
bers (Fig. 5a).
While lab assistant-related variability in the live cell
counts between the cell isolates could likely be decreased
by enhancement of lab staff training, potential donor-
individual influences cannot be eliminated prospectively.
Therefore, to limit a potential impact of ABCB5+ cell
isolate variability on the homogeneity of the drug sub-
stance batches produced thereof, we defined that the co-
efficient of variation of the cell count of a set of ABCB5+
cell isolates may not be greater than 50% for it to be
pooled into one drug substance batch (otherwise only
the isolates that did not vary by more than 50% from the
mean cell count of the whole set of isolates intended to
be pooled were ultimately pooled into a drug substance
batch). Applying this criterion, 64 of 66 isolate sets could
be pooled as a whole, the remaining two isolate sets at
least in part. Thus, in the future, this criterion could be
defined more strictly in order to further increase process
homogeneity. Of note, drug substance batch quality was
not negatively affected by this variability. Specifically,
only 8 out of 66 drug substance batches were rejected
due to specification failure (Table 2).
A key component in the quality assessment of cellular
therapy products is the evaluation of potency, in order
to guarantee biological functionality that is predictive of
clinical effectiveness. Considering that MSCs exert their
therapeutic effects through a variety of pathways that are
induced upon interaction with the host microenviron-
ment, which has constituted the paradigm of MSCs to
function as site-regulated, patient-specific “injury drug-
stores” [28], evaluation of a single pathway is thought in-
sufficient to predict clinical effectiveness [2]. We
therefore developed and implemented three potency as-
says reflecting the three clinically most relevant biologic
modes of action of ABCB5+ MSCs: (i) IL-1RA secretion
assay after co-culture with M1-polarized macrophages to
predict the anti-inflammatory potency in M1 macro-
phage dominated inflammatory tissue environment, (ii)
VEGF secretion assay in hypoxic culture conditions to
estimate the pro-angiogenic bioactivity in ischemic tissue
environment, and (iii) tube formation assay to demon-
strate the endothelial differentiation and blood vessel-
forming capacity of the produced cells. Except for 3
batches that failed to clearly form capillary structures in
the tube formation assay, all drug substance batches ful-
filled the specified criteria for all three assays (Fig. 5b,
Table 2). Notably, however, while these assays were vali-
dated to reliably detect biological activity and thus quali-
tatively confirm the potency of ex vivo-expanded
ABCB5+ MSCs, a quantitative correlation between the
assay values and the strength of clinical efficacy remains
to be elucidated. Comparisons between the outcomes of
the ongoing clinical trials and the assay data results will
offer valuable clues on quantitative potency prediction.
Conclusions
Taken together, the present GMP Product Quality Re-
view data demonstrate the high robustness of our cell
expansion and manufacturing process, enabling the gen-
eration of a homogenous, standardized, highly pure
(97.7% ABCB5+ MSCs), off-the-shelf available ATMP
with proven potency to be used for therapy of a variety
of skin-related and other, including systemic, inflamma-
tory and/or degenerative conditions. At present, clinical
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trials to confirm the preclinical safety and efficacy data
in various clinical indications are underway. Beyond
their clinical informative value, the outcomes of these
trials will also be used to refine the manufacturing
process design, aiming at continuously improving and
optimizing the procedures and control measures and,
consequently, the product.
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Tube formation assay on extracellular matrix gel. ABCB5+ mesenchymal
stem cells (1 × 105 and 1.5 × 105) were seeded in two wells of a Geltrex™-
coated 24-well plate and incubated for 19–22 h. Tube formation was eval-
uated visually according to the following categories: A tubular branches
of several cells forming a defined network-like structure; B tubular
branches of several cells clustering together forming broad strands, for-
mation of syncytia, areas of high cellular density lacking formation of
tubular branches; C cells clustering together, building nodes and forming
tubular branches that connect the nodes with each other; D only spor-
adic cells form tubular branches, partial node formation, but no or nearly
no connections between nodes, no or only sporadic apoptotic cells; E
largely apoptotic cells, no or only sporadic tubular branches; F no tubular
branches. Human umbilical vein endothelial cells (HUVEC) and human
skin melanoma cells (SK-MEL-28) served as positive and negative controls,
respectively. Categories A–C are considered as successful angiogenic dif-
ferentiation. Original total magnification × 40.
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